

Lynozytic™ (linvoseltamab-gcpt) (Intravenous)

Document Number: IC-0803

Last Review Date: 08/05/2025

Date of Origin: 08/05/2025

Dates Reviewed: 08/2025

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 6 months, following initial inpatient administration of 2 doses (step-up dose 1, step-up dose 2).
- Renewal: Prior authorization validity may be renewed every 6 months thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- Step-up Dosing
 - Day 1: 5 billable units (5 mg)
 - Day 8: 25 billable units (25 mg)
- Treatment Dosing
 - Day 15: 200 billable units (200 mg)
 - Weekly (starting one week after day 15 through week 13 for ten doses): 200 billable units (200 mg)
 - Bi-weekly (starting week 14 and every 2 weeks thereafter for at least 17 doses): 200 billable units (200 mg)
- Maintenance Dosing
 - Every 4 weeks (starting after at least week 24 and after at least 17 doses): 200 billable units (200 mg)

III. Initial Approval Criteria ¹

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Used as continuation therapy following inpatient administration of all step-up doses; **AND**
- Patient had an absence of unacceptable toxicity while on inpatient administration; **AND**

Universal Criteria ¹

- Patient does not have an active infection, including clinically important localized infections; **AND**
- Patient will be administered prophylaxis for infection (*e.g., antimicrobials, antibiotics, antifungals, antivirals, vaccines, and subcutaneous or intravenous immunoglobulin (IVIG)*) according to local guidelines; **AND**

- Patient immunoglobulin levels will be monitored prior to and during therapy and treated appropriately; **AND**
- Patient does not have active CNS involvement or clinical signs of meningeal involvement from multiple myeloma; **AND**
- Patient has not had an allogeneic stem cell transplant or an autologous stem cell transplant within the previous 12 weeks; **AND**

Multiple Myeloma †¹⁻³

- Patient has relapsed or refractory disease; **AND**
- Used as a single agent; **AND**
- Patient has received at least four (4) prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓞ Orphan Drug

IV. Renewal Criteria¹

Prior authorization validity may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: neurologic toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), severe administration-related/local injection-site reactions, cytokine release syndrome (CRS), hepatotoxicity, neutropenia/febrile neutropenia, severe infections, etc.

V. Dosage/Administration ^{1,8}

Indication	Dose			
Multiple Myeloma	<ul style="list-style-type: none"> The recommended dosage of Lynozyfic is step-up doses of 5 mg, 25 mg, and 200 mg, followed by 200 mg weekly for 10 doses, followed by 200 mg biweekly (every 2 weeks). In patients who have achieved and maintained very good partial response (VGPR) or better at or after Week 24 and received at least 17 doses of 200 mg, decrease the dosing frequency to 200 mg every 4 weeks. Continue treatment until disease progression or unacceptable toxicity. (See table below) 			
	Dosing schedule	Day ^a	Dose	
	Step-up dosing schedule	Day 1	Step-up dose 1	5 mg
		Day 8	Step-up dose 2	25 mg
		Day 15	First treatment dose	200 mg
	Weekly dosing schedule	One week after Day 15 treatment dose and once weekly from Week 4 to Week 13 for 10 treatment doses	Second and subsequent treatment doses	200 mg
	Biweekly (Every 2 Weeks) Dosing Schedule	Week 14 and every 2 weeks thereafter	Subsequent treatment doses	200 mg
	Patients who have achieved and maintained very good partial response (VGPR) or better at or after Week 24 and received at least 17 doses of 200 mg			
	Every 4 Weeks Dosing Schedule	At Week 24 or after and every 4 weeks thereafter.		200 mg
	– ^a Weekly doses should be at least 5 days apart. Biweekly doses should be at least 10 days apart. Every 4-week doses should be at least 24 days apart.			
<ul style="list-style-type: none"> Administer intravenously according to the step-up schedule to reduce the incidence and severity of cytokine release syndrome (CRS). Lynozyfic should be administered by a healthcare provider with immediate access to emergency equipment and appropriate medical support to manage severe reactions such as cytokine release syndrome (CRS), infusion-related reactions (IRR), and neurologic toxicity, including ICANS. Due to the risk of CRS and neurologic toxicity, including ICANS, patients should be hospitalized for 24 hours after administration of the first step-up dose, and for 24 hours after administration of the second step-up dose. 				

VI. Billing Code/Availability Information

HCPCS Code:

- C9307 – Injection, linvoseltamab-gcpt, 1 mg; 1 billable unit = 1 mg (Effective 01/01/2026)
- J9999 – Not otherwise classified, antineoplastic drugs

NDC:

- Lynozyfic 5 mg/2.5 mL (2 mg/mL) single-dose vial: 61755-0054-xx

- Lynozyfic 200 mg/10 mL (20 mg/mL) single-dose vial: 61755-0056-xx

VII. References

1. Lynozyfic [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; July 2025. Accessed July 2025.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for teclistamab. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed July 2025.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 2.2025. National Comprehensive Cancer Network, 2025. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed July 2025.
4. BGM Durie, J-L Harousseau, J S Miguel, et al on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. *Leukemia*. Sep; 20(9):1467-73.
5. Lee HC, Bumma N, Richter JR, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. *JCO* 41, 8006-8006(2023). DOI:10.1200/JCO.2023.41.16_suppl.8006.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.32	Solitary plasmacytoma in relapse
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologics. In addition, National Coverage Determinations (NCDs) and/or Local

Page 4

Medical Necessity Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2025 Prime Therapeutics Management, LLC



Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC